Loading…

Cost per DALY averted in low, middle- and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholds

Determining the cost-effectiveness thresholds for healthcare interventions has been a severe challenge for policymakers, especially in low- and middle-income countries. This study aimed to estimate the cost per disability-adjusted life-year (DALY) averted for countries with different levels of Human...

Full description

Saved in:
Bibliographic Details
Published in:Cost effectiveness and resource allocation 2021-02, Vol.19 (1), p.7-7, Article 7
Main Authors: Daroudi, Rajabali, Akbari Sari, Ali, Nahvijou, Azin, Faramarzi, Ahmad
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c563t-f9f5ade01fb779539ce7917e87bf9d092553b131e9c1378d2c58b541f8064f13
cites cdi_FETCH-LOGICAL-c563t-f9f5ade01fb779539ce7917e87bf9d092553b131e9c1378d2c58b541f8064f13
container_end_page 7
container_issue 1
container_start_page 7
container_title Cost effectiveness and resource allocation
container_volume 19
creator Daroudi, Rajabali
Akbari Sari, Ali
Nahvijou, Azin
Faramarzi, Ahmad
description Determining the cost-effectiveness thresholds for healthcare interventions has been a severe challenge for policymakers, especially in low- and middle-income countries. This study aimed to estimate the cost per disability-adjusted life-year (DALY) averted for countries with different levels of Human Development Index (HDI) and Gross Domestic Product (GDP). The data about DALYs, per capita health expenditure (HE), HDI, and GDP per capita were extracted for 176 countries during the years 2000 to 2016. Then we examined the trends on these variables. Panel regression analysis was performed to explore the correlation between DALY and HE per capita. The results of the regression models were used to calculate the cost per DALY averted for each country. Age-standardized rate (ASR) DALY (DALY per 100,000 population) had a nonlinear inverse correlation with HE per capita and a linear inverse correlation with HDI. One percent increase in HE per capita was associated with an average of 0.28, 0.24, 0.18, and 0.27% decrease on the ASR DALY in low HDI, medium HDI, high HDI, and very high HDI countries, respectively. The estimated cost per DALY averted was $998, $6522, $23,782, and $69,499 in low HDI, medium HDI, high HDI, and very high HDI countries. On average, the cost per DALY averted was 0.34 times the GDP per capita in low HDI countries. While in medium HDI, high HDI, and very high HDI countries, it was 0.67, 1.22, and 1.46 times the GDP per capita, respectively. This study suggests that the cost-effectiveness thresholds might be less than a GDP per capita in low and medium HDI countries and between one and two GDP per capita in high and very high HDI countries.
doi_str_mv 10.1186/s12962-021-00260-0
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_579b64f2cb414768812481d18c2a4aa7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A653685614</galeid><doaj_id>oai_doaj_org_article_579b64f2cb414768812481d18c2a4aa7</doaj_id><sourcerecordid>A653685614</sourcerecordid><originalsourceid>FETCH-LOGICAL-c563t-f9f5ade01fb779539ce7917e87bf9d092553b131e9c1378d2c58b541f8064f13</originalsourceid><addsrcrecordid>eNptUk2P0zAUjBCIXQp_gAOyxIUDWWwnjh0OSFX5WqkSl71wshz7uXWVxMVOivbX8Fd52y7LLkI-2Hqemec3nqJ4yegFY6p5lxlvG15SzkpKeUNL-qg4Z7VUpRS1fHzvfFY8y3mHoIpT9bQ4qypRs6qpz4tfq5gnsodEPi7X34k5QJrAkTCSPv58S4bgXA8lMaMj27DZlmG0cQBi4zxOKUB-T-AQHIwWiE9xINMWyKaPnelJNye8INETFzKYDCRPs7smUySQpzCYCY5wiy8owXuwUzjACDljOUHext7l58UTb_oML273RXH1-dPV6mu5_vblcrVcl1Y01VT61gvjgDLfSdmKqrUgWyZByc63jrZciKpjFYPWskoqx61QHXrgFW1qz6pFcXmSddHs9D7h69K1jiboYyGmjTZpCrYHLWTbIYfbrkZ_G6UYrxVzTFluamMkan04ae3nbgBnAZ0y_QPRhzdj2OpNPGipGvwYhQJvbgVS_DGjV3oI2ULfmxHinDX2k0zIGidfFK__ge7inEZ0ClEtqzmnUvxFbQwOEEYfsa-9EdXLRlSNEg2rEXXxHxQuB0OwcQQfsP6AwE8Em2LOCfzdjIzqm4TqU0I1JlQfE6opkl7dd-eO8ieS1W_mC-Ei</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2491422075</pqid></control><display><type>article</type><title>Cost per DALY averted in low, middle- and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholds</title><source>Publicly Available Content Database</source><source>ABI/INFORM Global</source><source>PubMed Central</source><creator>Daroudi, Rajabali ; Akbari Sari, Ali ; Nahvijou, Azin ; Faramarzi, Ahmad</creator><creatorcontrib>Daroudi, Rajabali ; Akbari Sari, Ali ; Nahvijou, Azin ; Faramarzi, Ahmad</creatorcontrib><description>Determining the cost-effectiveness thresholds for healthcare interventions has been a severe challenge for policymakers, especially in low- and middle-income countries. This study aimed to estimate the cost per disability-adjusted life-year (DALY) averted for countries with different levels of Human Development Index (HDI) and Gross Domestic Product (GDP). The data about DALYs, per capita health expenditure (HE), HDI, and GDP per capita were extracted for 176 countries during the years 2000 to 2016. Then we examined the trends on these variables. Panel regression analysis was performed to explore the correlation between DALY and HE per capita. The results of the regression models were used to calculate the cost per DALY averted for each country. Age-standardized rate (ASR) DALY (DALY per 100,000 population) had a nonlinear inverse correlation with HE per capita and a linear inverse correlation with HDI. One percent increase in HE per capita was associated with an average of 0.28, 0.24, 0.18, and 0.27% decrease on the ASR DALY in low HDI, medium HDI, high HDI, and very high HDI countries, respectively. The estimated cost per DALY averted was $998, $6522, $23,782, and $69,499 in low HDI, medium HDI, high HDI, and very high HDI countries. On average, the cost per DALY averted was 0.34 times the GDP per capita in low HDI countries. While in medium HDI, high HDI, and very high HDI countries, it was 0.67, 1.22, and 1.46 times the GDP per capita, respectively. This study suggests that the cost-effectiveness thresholds might be less than a GDP per capita in low and medium HDI countries and between one and two GDP per capita in high and very high HDI countries.</description><identifier>ISSN: 1478-7547</identifier><identifier>EISSN: 1478-7547</identifier><identifier>DOI: 10.1186/s12962-021-00260-0</identifier><identifier>PMID: 33541364</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Cost analysis ; DALY ; Expenditures ; GDP per capita ; HDI ; Health care expenditures ; Health expenditure ; Human Development Index ; Industrialized nations ; Intervention ; Medical care, Cost of ; Medical research ; Medicine, Experimental ; Opportunity costs ; Per capita ; Population ; Trends</subject><ispartof>Cost effectiveness and resource allocation, 2021-02, Vol.19 (1), p.7-7, Article 7</ispartof><rights>COPYRIGHT 2021 BioMed Central Ltd.</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c563t-f9f5ade01fb779539ce7917e87bf9d092553b131e9c1378d2c58b541f8064f13</citedby><cites>FETCH-LOGICAL-c563t-f9f5ade01fb779539ce7917e87bf9d092553b131e9c1378d2c58b541f8064f13</cites><orcidid>0000-0001-5661-8991</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863358/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2491422075?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11688,25753,27924,27925,36060,36061,37012,37013,44363,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33541364$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Daroudi, Rajabali</creatorcontrib><creatorcontrib>Akbari Sari, Ali</creatorcontrib><creatorcontrib>Nahvijou, Azin</creatorcontrib><creatorcontrib>Faramarzi, Ahmad</creatorcontrib><title>Cost per DALY averted in low, middle- and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholds</title><title>Cost effectiveness and resource allocation</title><addtitle>Cost Eff Resour Alloc</addtitle><description>Determining the cost-effectiveness thresholds for healthcare interventions has been a severe challenge for policymakers, especially in low- and middle-income countries. This study aimed to estimate the cost per disability-adjusted life-year (DALY) averted for countries with different levels of Human Development Index (HDI) and Gross Domestic Product (GDP). The data about DALYs, per capita health expenditure (HE), HDI, and GDP per capita were extracted for 176 countries during the years 2000 to 2016. Then we examined the trends on these variables. Panel regression analysis was performed to explore the correlation between DALY and HE per capita. The results of the regression models were used to calculate the cost per DALY averted for each country. Age-standardized rate (ASR) DALY (DALY per 100,000 population) had a nonlinear inverse correlation with HE per capita and a linear inverse correlation with HDI. One percent increase in HE per capita was associated with an average of 0.28, 0.24, 0.18, and 0.27% decrease on the ASR DALY in low HDI, medium HDI, high HDI, and very high HDI countries, respectively. The estimated cost per DALY averted was $998, $6522, $23,782, and $69,499 in low HDI, medium HDI, high HDI, and very high HDI countries. On average, the cost per DALY averted was 0.34 times the GDP per capita in low HDI countries. While in medium HDI, high HDI, and very high HDI countries, it was 0.67, 1.22, and 1.46 times the GDP per capita, respectively. This study suggests that the cost-effectiveness thresholds might be less than a GDP per capita in low and medium HDI countries and between one and two GDP per capita in high and very high HDI countries.</description><subject>Cost analysis</subject><subject>DALY</subject><subject>Expenditures</subject><subject>GDP per capita</subject><subject>HDI</subject><subject>Health care expenditures</subject><subject>Health expenditure</subject><subject>Human Development Index</subject><subject>Industrialized nations</subject><subject>Intervention</subject><subject>Medical care, Cost of</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Opportunity costs</subject><subject>Per capita</subject><subject>Population</subject><subject>Trends</subject><issn>1478-7547</issn><issn>1478-7547</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>M0C</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUk2P0zAUjBCIXQp_gAOyxIUDWWwnjh0OSFX5WqkSl71wshz7uXWVxMVOivbX8Fd52y7LLkI-2Hqemec3nqJ4yegFY6p5lxlvG15SzkpKeUNL-qg4Z7VUpRS1fHzvfFY8y3mHoIpT9bQ4qypRs6qpz4tfq5gnsodEPi7X34k5QJrAkTCSPv58S4bgXA8lMaMj27DZlmG0cQBi4zxOKUB-T-AQHIwWiE9xINMWyKaPnelJNye8INETFzKYDCRPs7smUySQpzCYCY5wiy8owXuwUzjACDljOUHext7l58UTb_oML273RXH1-dPV6mu5_vblcrVcl1Y01VT61gvjgDLfSdmKqrUgWyZByc63jrZciKpjFYPWskoqx61QHXrgFW1qz6pFcXmSddHs9D7h69K1jiboYyGmjTZpCrYHLWTbIYfbrkZ_G6UYrxVzTFluamMkan04ae3nbgBnAZ0y_QPRhzdj2OpNPGipGvwYhQJvbgVS_DGjV3oI2ULfmxHinDX2k0zIGidfFK__ge7inEZ0ClEtqzmnUvxFbQwOEEYfsa-9EdXLRlSNEg2rEXXxHxQuB0OwcQQfsP6AwE8Em2LOCfzdjIzqm4TqU0I1JlQfE6opkl7dd-eO8ieS1W_mC-Ei</recordid><startdate>20210204</startdate><enddate>20210204</enddate><creator>Daroudi, Rajabali</creator><creator>Akbari Sari, Ali</creator><creator>Nahvijou, Azin</creator><creator>Faramarzi, Ahmad</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88C</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>L.-</scope><scope>M0C</scope><scope>M0S</scope><scope>M0T</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5661-8991</orcidid></search><sort><creationdate>20210204</creationdate><title>Cost per DALY averted in low, middle- and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholds</title><author>Daroudi, Rajabali ; Akbari Sari, Ali ; Nahvijou, Azin ; Faramarzi, Ahmad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c563t-f9f5ade01fb779539ce7917e87bf9d092553b131e9c1378d2c58b541f8064f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cost analysis</topic><topic>DALY</topic><topic>Expenditures</topic><topic>GDP per capita</topic><topic>HDI</topic><topic>Health care expenditures</topic><topic>Health expenditure</topic><topic>Human Development Index</topic><topic>Industrialized nations</topic><topic>Intervention</topic><topic>Medical care, Cost of</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Opportunity costs</topic><topic>Per capita</topic><topic>Population</topic><topic>Trends</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Daroudi, Rajabali</creatorcontrib><creatorcontrib>Akbari Sari, Ali</creatorcontrib><creatorcontrib>Nahvijou, Azin</creatorcontrib><creatorcontrib>Faramarzi, Ahmad</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Global</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Cost effectiveness and resource allocation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Daroudi, Rajabali</au><au>Akbari Sari, Ali</au><au>Nahvijou, Azin</au><au>Faramarzi, Ahmad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost per DALY averted in low, middle- and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholds</atitle><jtitle>Cost effectiveness and resource allocation</jtitle><addtitle>Cost Eff Resour Alloc</addtitle><date>2021-02-04</date><risdate>2021</risdate><volume>19</volume><issue>1</issue><spage>7</spage><epage>7</epage><pages>7-7</pages><artnum>7</artnum><issn>1478-7547</issn><eissn>1478-7547</eissn><abstract>Determining the cost-effectiveness thresholds for healthcare interventions has been a severe challenge for policymakers, especially in low- and middle-income countries. This study aimed to estimate the cost per disability-adjusted life-year (DALY) averted for countries with different levels of Human Development Index (HDI) and Gross Domestic Product (GDP). The data about DALYs, per capita health expenditure (HE), HDI, and GDP per capita were extracted for 176 countries during the years 2000 to 2016. Then we examined the trends on these variables. Panel regression analysis was performed to explore the correlation between DALY and HE per capita. The results of the regression models were used to calculate the cost per DALY averted for each country. Age-standardized rate (ASR) DALY (DALY per 100,000 population) had a nonlinear inverse correlation with HE per capita and a linear inverse correlation with HDI. One percent increase in HE per capita was associated with an average of 0.28, 0.24, 0.18, and 0.27% decrease on the ASR DALY in low HDI, medium HDI, high HDI, and very high HDI countries, respectively. The estimated cost per DALY averted was $998, $6522, $23,782, and $69,499 in low HDI, medium HDI, high HDI, and very high HDI countries. On average, the cost per DALY averted was 0.34 times the GDP per capita in low HDI countries. While in medium HDI, high HDI, and very high HDI countries, it was 0.67, 1.22, and 1.46 times the GDP per capita, respectively. This study suggests that the cost-effectiveness thresholds might be less than a GDP per capita in low and medium HDI countries and between one and two GDP per capita in high and very high HDI countries.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>33541364</pmid><doi>10.1186/s12962-021-00260-0</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-5661-8991</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1478-7547
ispartof Cost effectiveness and resource allocation, 2021-02, Vol.19 (1), p.7-7, Article 7
issn 1478-7547
1478-7547
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_579b64f2cb414768812481d18c2a4aa7
source Publicly Available Content Database; ABI/INFORM Global; PubMed Central
subjects Cost analysis
DALY
Expenditures
GDP per capita
HDI
Health care expenditures
Health expenditure
Human Development Index
Industrialized nations
Intervention
Medical care, Cost of
Medical research
Medicine, Experimental
Opportunity costs
Per capita
Population
Trends
title Cost per DALY averted in low, middle- and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholds
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T19%3A45%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost%20per%20DALY%20averted%20in%20low,%20middle-%20and%20high-income%20countries:%20evidence%20from%20the%20global%20burden%20of%20disease%20study%20to%20estimate%20the%20cost-effectiveness%20thresholds&rft.jtitle=Cost%20effectiveness%20and%20resource%20allocation&rft.au=Daroudi,%20Rajabali&rft.date=2021-02-04&rft.volume=19&rft.issue=1&rft.spage=7&rft.epage=7&rft.pages=7-7&rft.artnum=7&rft.issn=1478-7547&rft.eissn=1478-7547&rft_id=info:doi/10.1186/s12962-021-00260-0&rft_dat=%3Cgale_doaj_%3EA653685614%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c563t-f9f5ade01fb779539ce7917e87bf9d092553b131e9c1378d2c58b541f8064f13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2491422075&rft_id=info:pmid/33541364&rft_galeid=A653685614&rfr_iscdi=true